StockData
Roivant Sciences Ltd. logo

Roivant Sciences Ltd.

ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.66−0.30 (-0.78%)

Close on Nov 20, 2026Market cap $27.92BP/E –Yield –

Roivant Sciences Arbutus Biopharma Corp. (ABUS) — G&A Expense by Quarter

Arbutus Biopharma Corp. (ABUS) — G&A Expense ($M)

Periods

Roivant Sciences Arbutus Biopharma Corp. (ABUS) — G&A Expense: $7.96M in Q2 FY2026, up 161.8% from a year earlier. That is the highest of the 20 quarters on record here.

Latest, Q2 FY2026
7.96
Period ended Sep 30, 2026 (CQ3 2026)
Change on a year earlier
+161.8%
3.04 in Q2 FY2025
History
20 quarters
Since Q1 FY2020
Sources
17
Documents cited below

Where the Q2 FY2026 figure comes from

Source: Arbutus Biopharma Corp. Form 10-Q (filed 2026-11-10) ↗

Reported in ABUS Form 10-K / 10-Q (XBRL).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedArbutus Biopharma Corp. (ABUS) — G&A Expense ($M)Year on yearSource
Q2 FY2026CQ3 2026Sep 30, 20267.96+161.8%Arbutus Biopharma Corp. Form 10-Q (filed 2026-11-10) ↗
Q1 FY2026CQ2 2026Jun 30, 20263.87+16.2%Arbutus Biopharma Corp. Form 10-Q (filed 2026-08-12) ↗
Q4 FY2025CQ1 2026Mar 31, 20265.89+1.0%Arbutus Biopharma Corp. Form 10-Q (filed 2026-05-13) ↗
Q2 FY2025CQ3 2025Sep 30, 20253.04-33.0%Arbutus Biopharma Corp. Form 10-Q (filed 2026-11-10) ↗
Q1 FY2025CQ2 2025Jun 30, 20253.33-55.9%Arbutus Biopharma Corp. Form 10-Q (filed 2026-08-12) ↗
Q4 FY2024CQ1 2025Mar 31, 20255.83+9.8%Arbutus Biopharma Corp. Form 10-Q (filed 2026-05-13) ↗
Q2 FY2024CQ3 2024Sep 30, 20244.54-22.3%Arbutus Biopharma Corp. Form 10-Q (filed 2025-11-13) ↗
Q1 FY2024CQ2 2024Jun 30, 20247.55+26.3%Arbutus Biopharma Corp. Form 10-Q (filed 2025-08-06) ↗
Q4 FY2023CQ1 2024Mar 31, 20245.31-4.3%Arbutus Biopharma Corp. Form 10-Q (filed 2025-05-14) ↗
Q2 FY2023CQ3 2023Sep 30, 20235.84+67.3%Arbutus Biopharma Corp. Form 10-Q (filed 2024-11-06) ↗
Q1 FY2023CQ2 2023Jun 30, 20235.98+15.0%Arbutus Biopharma Corp. Form 10-Q (filed 2024-08-08) ↗
Q4 FY2022CQ1 2023Mar 31, 20235.55+13.5%Arbutus Biopharma Corp. Form 10-Q (filed 2024-05-02) ↗
Q2 FY2022CQ3 2022Sep 30, 20223.49-16.5%Arbutus Biopharma Corp. Form 10-Q (filed 2023-11-07) ↗
Q1 FY2022CQ2 2022Jun 30, 20225.20+16.1%Arbutus Biopharma Corp. Form 10-Q (filed 2023-08-03) ↗
Q4 FY2021CQ1 2022Mar 31, 20224.89+26.0%Arbutus Biopharma Corp. Form 10-Q (filed 2023-05-04) ↗
Q2 FY2021CQ3 2021Sep 30, 20214.18+2.7%Arbutus Biopharma Corp. Form 10-Q ↗

Cite this data

StockData. (2026). Roivant Sciences Arbutus Biopharma Corp. (ABUS) — G&A Expense ($M), quarterly Q1 FY2020–Q2 FY2026 [Data set]. Compiled from Roivant Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/roiv/kpis/abus-ga-row

See every metric in the Roivant Sciences KPI table. Data updated Nov 16, 2026.

See a number that looks wrong?